Literature DB >> 1385775

Differential occurrence of CSF-like activity and transforming activity of Mos during the cell cycle in fibroblasts.

K Okazaki1, M Nishizawa, N Furuno, H Yasuda, N Sagata.   

Abstract

The Xenopus c-mos proto-oncogene product, Mosxe, possesses cytostatic factor (CSF) activity to arrest maturing oocytes in metaphase II and has weak transforming activity in mouse NIH3T3 cells. We show that Mosxe mutants bearing 'stabilizing' penultimate N-terminal amino acids are strongly transforming and can retard progression through the G2-M phases in Mosxe-transformed cells, probably via their CSF activity. On the other hand, a cyclin-Mosxe fusion protein, which undergoes abrupt degradation at the end of mitosis and is restored to its normal levels only after the G1 phase, transforms cells much less efficiently than a mutated cyclin-Mosxe fusion protein that is stable during M-G1 transition. Moreover, in low-serum medium, cells transformed by the unstable cyclin-Mosxe require a long period to enter the S phase, in contrast with the rapid entry into the S phase of cells transformed by the stable cyclin-Mosxe. These results provide strong evidence that unlike the physiological CSF activity, the transforming activity of Mos is exerted in the G1 phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385775      PMCID: PMC556719          DOI: 10.1002/j.1460-2075.1992.tb05309.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  68 in total

1.  The c-mos gene product is required for cyclin B accumulation during meiosis of mouse eggs.

Authors:  S J O'Keefe; A A Kiessling; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 2.  Cyclins and cancer.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

3.  Degradation of nuclear oncoproteins by the ubiquitin system in vitro.

Authors:  A Ciechanover; J A DiGiuseppe; B Bercovich; A Orian; J D Richter; A L Schwartz; G M Brodeur
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

4.  A point mutation in C-terminal region of cdc2 kinase causes a G2-phase arrest in a mouse temperature-sensitive FM3A cell mutant.

Authors:  H Yasuda; M Kamijo; R Honda; M Nakamura; F Hanaoka; Y Ohba
Journal:  Cell Struct Funct       Date:  1991-02       Impact factor: 2.212

5.  The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA.

Authors:  J W Taylor; J Ott; F Eckstein
Journal:  Nucleic Acids Res       Date:  1985-12-20       Impact factor: 16.971

Review 6.  Oocyte maturation.

Authors:  Y Masui; H J Clarke
Journal:  Int Rev Cytol       Date:  1979

7.  Expression of c-mos RNA in germ cells of male and female mice.

Authors:  D S Goldman; A A Kiessling; C F Millette; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

8.  Chicken homolog of the mos proto-oncogene.

Authors:  M Schmidt; M K Oskarsson; J K Dunn; D G Blair; S Hughes; F Propst; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

9.  Serine kinase activity associated with Maloney murine sarcoma virus-124-encoded p37mos.

Authors:  S A Maxwell; R B Arlinghaus
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

10.  Cyclin is a component of maturation-promoting factor from Xenopus.

Authors:  J Gautier; J Minshull; M Lohka; M Glotzer; T Hunt; J L Maller
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

View more
  12 in total

1.  Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.

Authors:  J H Yoon; J K Kim; G B Rha; M Oh; S H Park; R H Seong; S H Hong; S D Park
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos.

Authors:  Ilio Vitale; Laura Senovilla; Mohamed Jemaà; Mickaël Michaud; Lorenzo Galluzzi; Oliver Kepp; Lisa Nanty; Alfredo Criollo; Santiago Rello-Varona; Gwenola Manic; Didier Métivier; Sonia Vivet; Nicolas Tajeddine; Nicholas Joza; Alexander Valent; Maria Castedo; Guido Kroemer
Journal:  EMBO J       Date:  2010-02-25       Impact factor: 11.598

3.  The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase.

Authors:  M Brandeis; T Hunt
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

Review 4.  Cyclins and cyclin-dependent kinases: a biochemical view.

Authors:  J Pines
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

5.  Mos positively regulates Xe-Wee1 to lengthen the first mitotic cell cycle of Xenopus.

Authors:  M S Murakami; T D Copeland; G F Vande Woude
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

6.  Mos activates myogenic differentiation by promoting heterodimerization of MyoD and E12 proteins.

Authors:  J L Lenormand; B Benayoun; M Guillier; M Vandromme; M P Leibovitch; S A Leibovitch
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

7.  The casein kinase II beta subunit binds to Mos and inhibits Mos activity.

Authors:  M Chen; D Li; E G Krebs; J A Cooper
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

8.  Regulation of Raf-1-dependent signaling during early Xenopus development.

Authors:  A M MacNicol; A J Muslin; E L Howard; A Kikuchi; M C MacNicol; L T Williams
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

9.  Mos induces the in vitro activation of mitogen-activated protein kinases in lysates of frog oocytes and mammalian somatic cells.

Authors:  E K Shibuya; J V Ruderman
Journal:  Mol Biol Cell       Date:  1993-08       Impact factor: 4.138

10.  The 'second-codon rule' and autophosphorylation govern the stability and activity of Mos during the meiotic cell cycle in Xenopus oocytes.

Authors:  M Nishizawa; K Okazaki; N Furuno; N Watanabe; N Sagata
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.